Announcement PDF ASX Announcement Race Announces Key Senior Clinical Team Appointments ● Dr Jose Iglesias, a pharmaceutical industry veteran with more than 30 years of experience and expertise in oncology clinical trials appointed Chief Medical Officer ● Dr Simon Fisher appointed Vice President of Clinical, leveraging over 25 years of industry experience, including leadership roles at major pharmaceutical companies 5 May 2025 – Race Oncology Limited (‘Race’) is pleased to announce the appointments of Dr Jose Iglesias, who succeeds Dr Michelle Rashford as Chief Medical Officer (CMO), and Dr Simon Fisher to the newly created role of Vice President of Clinical. Both appointments are effective immediately. Dr Jose Iglesias is an internationally recognised pharmaceutical executive with a distinguished career spanning both major and emerging pharmaceutical companies. His appointment marks a significant addition to Race’s clinical leadership team. Dr Iglesias held key leadership roles at Abraxis BioScience, including Vice President of Global Clinical Development and Chief Medical Officer, where he oversaw the global development of the reformulated chemotherapeutic agent, Abraxane® (paclitaxel) and other pipeline assets. He later served as Vice President of Clinical Development at Celgene, successfully leading several Phase 3 clinical programs for Abraxane® in pancreatic, lung, and metastatic breast cancers. Dr Iglesias has also held senior medical leadership roles at Amgen, Bionomics, Biothera Pharmaceuticals, Apobiologix, and Eli Lilly, including as Head of Clinical Studies at Eli Lilly Australia. His has extensive experience interacting with global regulatory authorities, reimbursement agencies, oncology cooperative groups, and patient advocacy organisations. He serves as an independent oncology consultant, specialising in solid tumour oncology, immuno-oncology, and translational medicine, with a focus on early to mid-phase clinical development. A widely published expert in oncology, Dr. Iglesias’s work has garnered over 12,000 citations. Commenting on his appointment, Dr Jose Iglesias said: “I’m honoured to join Race Oncology at a critical juncture in the company's clinical development efforts. Race’s commitment to advancing innovative oncology therapies aligns closely with my commitment to improving outcomes for cancer patients. I look forward to contributing my experience in early-phase and translational oncology development to help accelerate the progression of RC220 and bring this novel therapy to patients." Dr Simon Fisher is a physician and accomplished pharmaceutical executive leader with a wealth of experience across global medical affairs, clinical development, regulatory strategy, and executive management. With an extensive background in both clinical medicine and business leadership, Dr Fisher has driven the development and successful commercialisation of innovative therapies and medical technologies in multiple therapeutic areas, including oncology, immunology, cardiology and respiratory medicine. Over the course of his career, he has held medical leadership roles in major pharmaceutical companies including Novartis, AstraZeneca, and Bristol-Myers Squibb. Notably, he has led and contributed to the Race Oncology Ltd • ABN 61 149 318 749 L36, 1 Macquarie Place Sydney NSW 2000 • T. +61 2 8051 3043 • E. info@raceoncology.com • www.raceoncology.com development and launch of more than 25 new medicines and medical devices globally, helping to transform healthcare delivery and improve patient outcomes. In his most recent role, Dr Fisher served as the Senior Medical Director at Johnson & Johnson in Australia/New Zealand, where he led MedTech medical affairs and clinical trials and was instrumental in driving new medical technology strategies. Prior to that, he was Chief Scientific Officer and Medical Director at Novartis Australia/New Zealand, where he successfully launched more than 15 new medicines and indications and drove significant growth for the company. As Vice President of Clinical at Race Oncology Limited, Dr Fisher will play a critical role in advancing the company's oncology drug RC220, focusing on its clinical development and driving strategic clinical partnerships. Commenting on his appointment, Dr Simon Fisher said: “Stepping into this role at Race presents an opportunity to contribute to the advancement of an important, emerging area of oncology. This program has the potential to address a significant gap in patient care and deliver meaningful benefits to patients facing chemotherapeutic intervention. I’m pleased to be joining such a talented and innovative team, united by a clear commitment to transforming patient outcomes.” Race Chief Executive Officer, Dr Daniel Tillett said: “We are very pleased to welcome Dr Jose Iglesias and Dr Simon Fisher to Race Oncology as we continue building momentum with our RC220 clinical programs and commercial strategy. Dr Iglesias brings a wealth of global oncology experience and strategic insight that will be instrumental as we advance our clinical programs. Dr Fisher’s appointment further strengthens our day-to-day leadership team, ensuring we have the depth and expertise to execute our ambitious development plans. I sincerely thank Dr Michelle Rashford for her valuable contributions as Chief Medical Officer during her time with Race. Her leadership and strategic guidance have been important in shaping our clinical direction, and we are deeply grateful for her dedication and contribution. I wish her well in her future endeavours.” Dr Iglesias, based in Canada, will serve in a consulting capacity, while Dr Fisher, based in Sydney, will be a full-time Race employee. -ENDS- About Race Oncology (ASX: RAC) Race Oncology (ASX: RAC) is an ASX-listed clinical stage biopharmaceutical company with a dedicated mission to be at the heart of cancer care. Race’s lead asset, bisantrene, is a small molecule anticancer drug. Bisantrene has a rich and unique clinical history with demonstrated therapeutic benefits in both adult and paediatric patients, a well characterised safety profile, and compelling clinical data demonstrating an anticancer effect with less cardiotoxicity compared to anthracyclines such as doxorubicin. Race is advancing a reformulated bisantrene (RC220) to address the high unmet needs of patients across multiple oncology indications, with a clinical focus on anthracycline combinations, where we hope to deliver cardioprotection and enhanced anticancer activity in solid tumours. Race is also exploring RC220 as a low-intensity treatment for acute myeloid leukaemia. Race Oncology Ltd • ABN 61 149 318 749 L36, 1 Macquarie Place Sydney NSW 2000 • T. +61 2 8051 3043 • E. info@raceoncology.com • www.raceoncology.com Race is investigating the effect of bisantrene on the m6A RNA pathway, following independent research published by the City of Hope identifying bisantrene as a potent inhibitor of FTO (Fat mass and obesityassociated protein). Dysregulation of the m6A RNA pathway has been described in numerous peer reviewed studies as a driver of a diverse range of cancers. Race Oncology has collaborated with Astex, City of Hope, MD Anderson, Sheba City of Health, UNC School of Medicine, University of Wollongong and University of Newcastle, and is actively exploring partnerships, licence agreements or a commercial merger and acquisition to accelerate access to bisantrene for patients with cancer across the world. Learn more at www.raceoncology.com. If you have any questions on this announcement or any past Race Oncology announcements, please go to the Interactive Announcements page in our Investor Hub https://announcements.raceoncology.com Race encourages all investors to go paperless by registering their details with the Company’s share registry, Automic Registry Services, at www.automicgroup.com.au. Release authorised by: Media contact: Daniel Tillett, CEO info@raceoncology.com Jane Lowe +61 411 117 774 jane.lowe@irdepartment.com.au Race Oncology Ltd • ABN 61 149 318 749 L36, 1 Macquarie Place Sydney NSW 2000 • T. +61 2 8051 3043 • E. info@raceoncology.com • www.raceoncology.com